Introduction: Addressing Organ Shortage, Cold Ischemia Injury, and Marginal Organ Utilization
For transplant surgeons, organ procurement organizations (OPOs), and transplant hospital administrators, the global organ shortage remains a critical challenge. Over 100,000 patients are on transplant waiting lists in the US alone, with 20–30% dying or becoming too sick for transplant before an organ becomes available. Traditional cold static storage (CSS) – flushing organs with preservation solution and storing on ice (0–4°C) – limits preservation time (heart 4–6 hours, liver 8–12 hours, kidney 24–36 hours, lung 6–8 hours), causes cold ischemia injury (cellular swelling, mitochondrial dysfunction), and offers no real-time assessment of organ viability. Ex vivo organ perfusion technology addresses these limitations by maintaining organs outside the body in a functioning state (normothermic 37°C or hypothermic 4–10°C) while continuously perfusing with oxygenated blood or preservation solution containing nutrients, medications, and metabolic substrates. Benefits include extended preservation time (12–24+ hours), real-time viability assessment (metabolic function, vascular resistance, bile production, gas exchange), and reconditioning of marginal organs (donation after cardiac death DCD, steatotic livers, aged kidneys). As transplant waiting lists grow, organ discard rates remain high (20–30% of donated organs are discarded), and normothermic perfusion technology gains regulatory approval (FDA, CE Mark), demand for ex vivo organ perfusion systems is emerging. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Ex Vivo Organ Perfusion Technology – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Ex Vivo Organ Perfusion Technology market, including market size, share, demand, industry development status, and forecasts for the next few years.
For transplant hospital administrators, OPO directors, and medical device investors, the core pain points include achieving organ viability assessment (metabolic, functional), extending preservation time (logistics, cross-match, recipient preparation), and reducing discard rates (marginal organs, DCD). According to QYResearch, the global ex vivo organ perfusion technology market was valued at US$ [value] million in 2025 and is projected to reach US$ [value] million by 2032, growing at a CAGR of [%] .
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5751917/ex-vivo-organ-perfusion-technology
Market Definition and Core Capabilities
Ex vivo organ perfusion technology preserves and maintains organs outside the body in a functioning state by continuously perfusing with specialized solution, enabling assessment, preservation, and treatment before transplantation. Core capabilities:
- Heart Perfusion (25–30% of revenue, largest segment): Normothermic (37°C) or hypothermic (4–10°C) perfusion. TransMedics Organ Care System (OCS) Heart – FDA-approved, extends preservation time (4–6 hours cold static to 12+ hours), enables viability assessment (cardiac output, coronary flow, lactate metabolism, troponin). Used for DCD hearts, high-risk donor hearts.
- Liver Perfusion (25–30% of revenue): Normothermic (OrganOx metra, TransMedics OCS Liver) – 12–24+ hours preservation, viability assessment (bile production, lactate clearance, transaminases). Hypothermic (Bridge to Life LifePort) – 12–18 hours preservation, reduced metabolic demand. Used for DCD livers, steatotic livers, aged livers, and split-liver transplantation.
- Kidney Perfusion (20–25% of revenue): Hypothermic (4–10°C) machine perfusion (Bridge to Life LifePort, Organ Recovery Systems). Extends preservation time (24–36 hours cold static to 48+ hours), enables viability assessment (vascular resistance, flow, urinary output). Used for DCD kidneys, aged kidneys, expanded criteria donors (ECD).
- Lung Perfusion (20–25% of revenue, fastest-growing at 12–14% CAGR): Normothermic (TransMedics OCS Lung, XVIVO Perfadex, Lung Bioengineering). Extends preservation time (6–8 hours cold static to 12+ hours), enables viability assessment (gas exchange, pulmonary artery pressure, compliance, bronchoscopy). Used for DCD lungs, marginal lungs, and ex vivo lung reconditioning (repair, treatment).
Market Segmentation by End User
- Organ Transplant Specialist Hospitals (60–65% of revenue, largest segment): High-volume transplant centers (100–500+ transplants/year). Normothermic and hypothermic perfusion systems for heart, liver, kidney, lung. Procurement by transplant surgery departments, perfusion services, and hospital administration. North America and Europe dominant.
- Organ Banks (20–25% of revenue): Organ procurement organizations (OPOs), tissue banks, and eye banks. Hypothermic perfusion for kidney, liver. Focus on organ preservation, logistics, and distribution. Growing demand for extended preservation (matching recipient, cross-country transport).
- Pharmaceutical Research Organizations (10–15% of revenue, fastest-growing at 12–14% CAGR): Drug testing (hepatotoxicity, nephrotoxicity, cardiotoxicity), organ preservation research, and regenerative medicine. Normothermic perfusion for pre-clinical studies, organ reconditioning (gene therapy, stem cell therapy, pharmacological intervention). Academic medical centers, CROs, and biotech.
Technical Challenges and Industry Innovation
The industry faces four critical hurdles. Normothermic perfusion complexity – requires oxygenated blood (donor or synthetic), nutrient solution (glucose, amino acids, lipids, electrolytes), medications (antibiotics, anticoagulants, vasodilators), temperature control (37°C), and physiological monitoring (flow, pressure, oxygen consumption, lactate, pH). Higher cost ($100k–500k per system, $5k–20k per perfusion) than cold storage ($500–2k). Viability assessment standardization – no consensus on predictive parameters (liver: bile production, lactate clearance, transaminase release; heart: cardiac output, coronary flow, lactate metabolism; lung: gas exchange, compliance; kidney: urine output, vascular resistance). Clinical validation studies ongoing. Logistics and transportation – perfusion systems are bulky (50–200 kg), require power, oxygen, and trained perfusionists. Portable systems (TransMedics OCS, OrganOx metra) enable mobile perfusion (ambulance, aircraft). Reimbursement and cost-effectiveness – normothermic perfusion adds $10k–50k per transplant vs. cold storage ($2k–5k). Reduced discard rates (10–20% increase in organ utilization) and improved outcomes (reduced delayed graft function, primary non-function, length of stay) justify additional cost.
独家观察: Lung Perfusion Fastest-Growing Segment for DCD & Marginal Lungs
An original observation from this analysis is the double-digit growth (12–14% CAGR) of ex vivo lung perfusion (EVLP) for DCD (donation after cardiac death) and marginal lungs (poor gas exchange, edema, contusion, aspiration). Only 20–30% of donor lungs are accepted for transplant (vs. 80–90% for kidneys, livers). EVLP enables assessment (gas exchange, compliance, pulmonary artery pressure) and reconditioning (antibiotics, steroids, surfactant, gene therapy). Lung transplant volume increased 15–20% at EVLP centers (Toronto General Hospital, Cleveland Clinic, Columbia, Duke). EVLP segment projected 30%+ of ex vivo perfusion revenue by 2030 (vs. 20% in 2025). Additionally, normothermic regional perfusion (NRP) for DCD abdominal organs (liver, kidneys) is emerging to improve outcomes (reduced ischemia-reperfusion injury, primary non-function). NRP uses extracorporeal membrane oxygenation (ECMO) to reperfuse abdominal organs in situ before recovery. NRP adopted in Europe, UK, and select US centers.
Strategic Outlook for Industry Stakeholders
For CEOs, product line managers, and medical device investors, the ex vivo organ perfusion technology market represents an emerging (high-growth), life-saving opportunity anchored by organ shortage, transplant waiting list mortality, and marginal organ utilization. Key strategies include:
- Investment in normothermic lung perfusion systems (DCD, marginal lungs, ex vivo reconditioning) for fastest-growing segment (transplant volume increase, discard rate reduction).
- Development of portable, integrated perfusion systems (lightweight, battery-powered, oxygen concentrator) for mobile organ transport (ambulance, aircraft) and remote OPOs.
- Expansion into normothermic regional perfusion (NRP) for DCD abdominal organs (liver, kidneys) with ECMO technology and organ viability assessment.
- Geographic expansion into North America and Europe for transplant center adoption, OPO partnerships, and regulatory approval (FDA, CE Mark, PMDA).
Companies that successfully combine organ-specific perfusion, viability assessment, and portable design will capture share in a multi-billion dollar market by 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
